Press release
Non-Alcoholic Steatohepatitis Biomarkers Market Trends Analysis, Market Opportunities, Key Players, Share And Forecast To 2033
Non-Alcoholic Steatohepatitis Biomarkers Market
According to The Business Research Company's, The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.11 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 25.6%. The growth in the historic period can be attributed to diabetes and metabolic syndrom, awareness and screening programs, liver biopsy limitations, regulatory support, shift towards personalized medicine, clinical trials in nash..
The non-alcoholic steatohepatitis biomarkers market will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to emergence of novel therapies, expansion of precision medicine approaches, patient advocacy initiatives, integration of multi-omics data, enhanced patient engagement.. Major trends in the forecast period include telemedicine and remote monitoring, innovative diagnostic platforms, global collaborations in research, technological advancements in biomarker discovery, integration of artificial intelligence (ai), inclusion of imaging biomarkers..
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report
Market Drivers and Trends:
The growing prevalence of liver cancer is expected to propel the growth of the non-alcoholic steatohepatitis biomarkers market going forward. Liver cancer refers to the development of malignant tumors within the liver and can start in the liver itself (primary liver cancer) or spread to the liver from other parts of the body (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers are used in liver cancer for early detection, disease progression monitoring, and treatment response assessment, to provide prognostic information, and can help reduce the need for invasive procedures. For instance, in October 2022, according to the Journal of Hepatology, a Switzerland-based medical journal that primarily focuses on hepatology, according to recent studies, hepatitis B virus (HBV) is thought to be responsible for about 56% of liver cancer cases. Therefore, the growing prevalence of liver cancer is driving the growth of the non-alcoholic steatohepatitis biomarkers market.
Technological advancements are a key trend in gaining popularity in the non-alcoholic steatohepatitis biomarkers market. Major companies operating in the non-alcoholic steatohepatitis biomarkers market are focused on developing innovative solutions to strengthen their position in the market. For instance, in October 2022, GENFIT, a France-based late-stage biopharmaceutical company, and LabCorp, a US-based life sciences company, agreed on a five-year exclusive licensing deal for GENFIT's NIS4 technology to aid in identifying patients with non-alcoholic-steatohepatitis-at-risk (NASH). NIS4 technology is an innovative, multi-biomarker-based algorithm specifically developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F > 2), also referred to as at-risk NASH. As part of the agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada, giving widespread access to healthcare professionals.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
Major Key Players of the Market:
Genfit SA; Prometheus Laboratories Inc.; Siemens Medical Solutions USA Inc.; BioPredictive; Quest Diagnostics; AstraZeneca Plc.; Laboratory Corporation of America Holdings; Pfizer Inc.; Bristol-Myers Squibb Company; NGM Biopharmaceuticals Inc.; Gilead Sciences Inc.; Perspectum Diagnostics Ltd.; One Way Liver SL; Enterome SA; Echosens SA; Cisbio Bioassays SAS; Celerion Inc.; Xeptagen SpA; Boehringer Ingelheim GmbH Inc.; Exalenz Bioscience Ltd.; Novartis AG; Novo Nordisk A/S; Allergan PLC.; Glympse Bio; HistoIndex Pte Ltd; Cirius Therapeutics; Intercept Pharmaceuticals; Viking Therapeutics; Madrigal Pharmaceuticals; Galmed Pharmaceuticals; Conatus Pharmaceuticals; Immuron Ltd; Metacrine
Non-Alcoholic Steatohepatitis Biomarkers Market 2024 Key Insights:
• The non-alcoholic steatohepatitis biomarkers market will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%.
• Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market
• Advancements In Nis4 Technology Pave The Way For Innovative Blood-Based Molecular Diagnostic Test
• North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=9002&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis Biomarkers Market Trends Analysis, Market Opportunities, Key Players, Share And Forecast To 2033 here
News-ID: 3750432 • Views: …
More Releases from The Business Research Company
Seed Treatment Fungicides Market to Grow at 9.3% CAGR, Reaching $3.15 Billion by …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Seed Treatment Fungicides Market Outlook: How is the Market Expected to Grow by 2025?
Over the past few years, the market for seed treatment fungicides has seen robust growth. Its market value is projected to rise from $2.07 billion in 2024 to $2.21 billion in 2025, signifying a compound annual…
Rheology Modifiers Market Growth to be Driven by Emerging Trends | $10.92 Billio …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Rheology Modifiers Industry?
There has been a consistent expansion in the size of the rheology modifiers market in the past few years. The market, which was worth $8.59 billion in 2024, is projected to increase to $8.89 billion in 2025, demonstrating a compound…
Polyurethane Foam Market to Record 8.4% CAGR Growth Through 2029 | Global Analys …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Polyurethane Foam Market Outlook: How is the Market Expected to Grow by 2025?
In recent years, the size of the polyurethane foam market has experienced substantial growth. It is projected to increase from a value of $54.27 billion in 2024 to $57.26 billion in 2025, indicating a compound annual growth…
Pharmaceutical Intermediates Market Size to Reach $46.04 Billion by 2029 | Growt …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Pharmaceutical Intermediates Industry?
There has been consistent growth in the market size of pharmaceutical intermediates over the past few years. The market is predicted to increase from a value of $33.37 billion in 2024, up to $34.95 billion in 2025, with a compound…
More Releases for Steatohepatitis
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.67 billion In 2028…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
